From dosing guidance to videos on injection procedure, these resources for healthcare professionals are designed to make the transition to home use as smooth as possible for patients prescribed Xolair.
Resources for healthcare professionals
DOSING TABLE
This table is designed to help you identify the correct dosage for your SAA patients.
INJECTION CALCULATOR
This table is designed to help you identify the number of injections required and the number of boxes per 3-month supply for each dose as per the self-administration guidance algorithm (below).
SELF-ADMINISTRATION GUIDANCE
This algorithm is designed to help you identify which patients may be suitable for self-administration.
Resources for patients
SELF-ADMINISTRATION STARTER KIT
This patient kit contains: 4x A6 booklets, 1x medical emergency card, 1x magnetic dosing card and 1x MyTherapy app flyer. Please contact a Novartis representative to order this material.
SELF-ADMINISTRATION DISCUSSION GUIDE
This A4 landscape desktop flipchart can be used to facilitate discussions between healthcare professionals and patients being treated with Xolair. Please contact a Novartis representative to order this material.
INJECTION VIDEOS
There are two videos showing the injection procedure for both patients and carers.
Patient
Carer
MYTHERAPY APP
This can only be accessed via the QR code on the flipchart discussion guide, MyTherapy app flyer or here. It is a private module of the MyTherapy app for patients prescribed Xolair for SAA. Patients can track injections and symptoms, generate reminders and access how-to videos showing correct injection technique.
The MyTherapy app is run by SmartPatient, and Novartis has paid for this private module specifically for patients prescribed Xolair for SAA.
*Xolair provides clinically meaningful improvements in quality of life for patients with severe allergic asthma.1
Indication2: Xolair should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma. In adults and adolescents (12 years of age and older): Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 <80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist. In children (6 to <12 years of age): Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.
FEV1, forced expiratory volume in 1 second; IgE, immunoglobulin E; SAA, severe allergic asthma.
References
- Braunstahl GJ et al. Resp Med 2013;107(8):1141–1151.
- Xolair® (omalizumab) Summary of Product Characteristics.
